CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects
Mark Y Chan, Karen Tan, Huay-Cheem Tan, Pei-Tee Huan, Bei Li, Qian-Hui Phua, Hong-Kai Lee, Chi-Hang Lee, Adrian Low, Richard C Becker, Wen-Chong Ong, Mark A Richards, Agus Salim, E-Shyong Tai, Evelyn Koay
Pharmacogenomics | FUTURE MEDICINE LTD | Published : 2012
AIM, MATERIALS & METHODS: We investigated the functional significance of CYP2C19*2, *3, *17 and PON1 Q192R SNPs in 89 consecutive Asian patients on clopidogrel treatment and the prevalence of functionally significant polymorphisms among 300 Chinese, Malays and Asian Indians.Both CYP2C19 loss-of-function alleles (*2 or *3) were associated with higher platelet reactivity while the CYP2C19 gain-of-function allele (*17) had lower platelet reactivity. For PON1, the median PRI was not significantly different between the QQ, QR and RR groups. The allele frequencies of CYP2C19*2, CYP2C19*3 and CYP2C19*17 were 0.280, 0.065 and 0.010 (rare) for Chinese, 0.310, 0.050 and 0.025 for Malays, and 0.375, 0...View full abstract
Awarded by National Medical Research Council (Singapore)
This study was supported by grants from the National Medical Research Council (Singapore, grant no. NIG09May023), the Cardiovascular Research Institute (Singapore) and Opto Systems Pte Ltd (Singapore). M Chan is supported by a clinician-scientist award (NMRC/CSA/028/2010) from the National Medical Research Council (Singapore). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.